Biopharma Update on the Novel Coronavirus: April 27

With the number of high false-positives from some antibody tests,  the FDA is bearing the brunt of criticism for allowing so many tests onto the market without properly vetting them. At the beginning of April, the U.S. Food and Drug Administration approved the first antibody test for COVID-19. Since then, the regulatory agency has allowed more than 100 antibody tests onto the market without full review and that has proven to become a problem as some tests are not as accurate as hoped. BioSpace